Pregnancy and secondary cancer after allogeneic bone marrow transplantation
Secondary cancer is a well known potential complication after allogeneic bone marrow transplantation (BMT). Among secondary malignancies, solid tumours usually develop late after transplant and are more frequently observed in patients receiving irradiation as part of the conditioning regimen. 1 Other risk factors have been variably identified and include underlying disease, age, sex, GVHD, use of ATG and therapy with azathioprine. [1] [2] [3] As the number of post-transplant long-term survivors is steadily increasing, further events occurring late after BMT could influence the emergence of secondary cancers. We report the case of a female patient treated with allogeneic BMT for acute lymphoblastic leukaemia (ALL), who developed a solid tumour during pregnancy.
A 21-year-old woman was diagnosed in December 1982 as having L2-common ALL. Following induction chemotherapy, she entered complete remission (CR) in January 1983 and after consolidation and maintenance went offtherapy in February 1984. In March 1987, an extramedullary relapse occurred in the left jaw bone. Second CR was achieved by combination chemotherapy and 4.4 Gy local radiotherapy. In December 1987, the patient underwent allogeneic BMT from her HLA-identical sister. Conditioning consisted of 12 Gy TBI administered in 6 fractions over 3 days at a dose-rate of 18 cGy/min in air, followed by cyclophosphamide at a dose of 120 mg/kg. As GVHD prophylaxis, she received cyclosporine alone. She engrafted at day 15 and experienced grade 2 acute GVHD, successfully treated with standard-dose corticosteroids. No other major complications were observed during the post-transplant course.
In December 1990, measurement of gonadotrophins indicated therapeutic castration. Following hormonal replacement therapy with alternating ethinyloestradiol and medroxyprogesterone acetate, the patient recovered her normal menstrual periods. In July 1994, she became pregnant by natural conception. At 29 weeks gestation (8 years from local radiotherapy and 7 years from BMT), clinical examination revealed the presence of a solid mass rising from the base of the tongue. Histologic examination was consistent with a diagnosis of highly undifferentiated adenocarcinoma. A CT scan showed involvement of local tissues and nodes. In March 1995 (34th week of gestation), the patient delivered a normal female baby of 1.9 kg body weight, by Cesarean section. Following combined chemo-radiotherapy, a partial clinical response was temporarily obtained, but the patient, who was in continuous CR from leukaemia, died in June 1996 because of cancer progression. At last follow-up, development of the child had been normal.
To our knowledge, this is the first case of a secondary solid tumour arising during pregnancy after allogeneic BMT. With the clinical history of our patient, radiotherapy is certainly the most important factor related to the development of the cancer, whose occurrence during pregnancy might be purely coincidental. However, a contributory role of the pregnancy in the development of this secondary tumour cannot be ruled out.
An association between pregnancy and replase of chronic myeloid leukaemia after transplant has been reported, suggesting suppression of the graft-versus-leukaemia (GVL) effect during pregnancy as the mechanism favouring relapse. 4, 5 It is therefore likely that immunological tolerance towards the fetus might increase the risk of secondary cancer in female transplant patients by reducing general immune surveillance against tumours. Pregnancy is a rare event after BMT, but on longer posttransplant follow-up spontaneous recovery of ovarian function, particularly in young women, and the practice of assisted conception could increase the number of pregnancies. 6 Therefore, as suggested by this case, clinicians should be aware that pregnancy might favour the development of secondary cancers after BMT.
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